Price T Rowe Associates Inc. MD increased its position in AnaptysBio Inc (NASDAQ:ANAB) by 18.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 937,273 shares of the biotechnology company’s stock after buying an additional 147,292 shares during the quarter. Price T Rowe Associates Inc. MD owned about 3.46% of AnaptysBio worth $52,881,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in ANAB. Invesco Ltd. lifted its holdings in shares of AnaptysBio by 25,030.8% during the second quarter. Invesco Ltd. now owns 1,097,462 shares of the biotechnology company’s stock valued at $61,919,000 after purchasing an additional 1,093,095 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of AnaptysBio by 13.4% during the second quarter. BlackRock Inc. now owns 2,050,390 shares of the biotechnology company’s stock valued at $115,681,000 after purchasing an additional 242,187 shares during the last quarter. Redmile Group LLC lifted its holdings in shares of AnaptysBio by 36.5% during the first quarter. Redmile Group LLC now owns 496,918 shares of the biotechnology company’s stock valued at $36,300,000 after purchasing an additional 132,868 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of AnaptysBio during the first quarter valued at $5,114,000. Finally, Jennison Associates LLC lifted its holdings in shares of AnaptysBio by 68.5% during the second quarter. Jennison Associates LLC now owns 162,422 shares of the biotechnology company’s stock valued at $9,164,000 after purchasing an additional 66,031 shares during the last quarter.
Shares of ANAB stock opened at $34.21 on Friday. AnaptysBio Inc has a fifty-two week low of $29.43 and a fifty-two week high of $97.89. The stock’s 50-day moving average is $41.50 and its two-hundred day moving average is $60.36. The firm has a market cap of $847.94 million, a P/E ratio of -13.68 and a beta of 1.50.
Several equities research analysts have recently commented on the company. Cantor Fitzgerald set a $140.00 target price on AnaptysBio and gave the company a “buy” rating in a report on Tuesday, August 20th. HC Wainwright set a $126.00 target price on AnaptysBio and gave the stock a “buy” rating in a research report on Monday, June 24th. Wedbush reaffirmed an “outperform” rating on shares of AnaptysBio in a research report on Tuesday. Stifel Nicolaus reaffirmed a “hold” rating on shares of AnaptysBio in a research report on Monday. Finally, Credit Suisse Group reaffirmed a “neutral” rating and issued a $48.00 target price (down from $75.00) on shares of AnaptysBio in a research report on Thursday. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. AnaptysBio presently has a consensus rating of “Buy” and an average target price of $99.63.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.